Daniel A. Gamache
39Patents
9h-index
34Co-inventors
75Inventor score
Filing activity: Jun 7, 1995 → Dec 4, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5696166A | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders | Human Necessities | 53 | Expired |
| US6872382B1 | Use of selective PDE IV inhibitors to treat dry eye disorders | Human Necessities | 43 | Expired |
| US6174878A | Topical use of kappa opioid agonists to treat otic pain | Human Necessities | 32 | Expired |
| US5811438A | Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products | Chemistry; Metallurgy | 31 | Expired |
| US8791154B2 | High concentration olopatadine ophthalmic composition | Chemistry; Metallurgy | 27 | Active |
| US6353022B1 | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders | Chemistry; Metallurgy | 22 | Expired |
| US5643943A | Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis | Chemistry; Metallurgy | 21 | Expired |
| US5686488A | Polyethoxylated castor oil products as anti-inflammatory agents | Human Necessities | 17 | Expired |
| US6645978B1 | Lipoxin A4 and its analogs for the treatment of dry eye | Human Necessities | 14 | Expired |
| US6429227B1 | Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders | Chemistry; Metallurgy | 8 | Expired |
| US6191126A | Topical use of .kappa. opioid agonists to treat ocular pain | Human Necessities | 8 | Expired |
| US6174914A | Method of inhibiting cytokine release from human ocular cells | Human Necessities | 6 | Expired |
| US6638976B2 | Method of treating neurodegenerative disorders of the retina and optic nerve head | Human Necessities | 6 | Expired |
| US8017592B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 4 | Active |
| US6353012B1 | 15-Hydroxyeicosatetraenoic acid-related compounds and methods of use | Chemistry; Metallurgy | 4 | Expired |
| US8222227B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 2 | Active |
| US7026296B2 | Methods of treating dry eye disorders | Human Necessities | 2 | Expired |
| US6225332A | Compositions containing histamine H2 agonists and methods of use in treating allergy and inflammation | Human Necessities | 2 | Expired |
| US8138205B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | Chemistry; Metallurgy | 1 | Active |
| US7923471B2 | Method of treating dry eye disorders and uveitis | Human Necessities | 1 | Active |
| US6825232B2 | Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders | Human Necessities | 1 | Expired |
| US6696453B2 | Use of NF-&kgr;B inhibitors to treat dry eye disorders | Human Necessities | 1 | Expired |
| US8618278B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 1 | Active |
| US6645994B1 | Method of treating dry eye disorders | Human Necessities | 1 | Expired |
| US9206428B2 | RNAi-mediated inhibition of histamine receptor H1-related conditions | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.